Research statistics

PE-22-28 research: publications and trials

What has been published on PE-22-28: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether PE-22-28 works or is safe. For what it is and what the studies found, see the PE-22-28 profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

1

Since 2017

Publications in 2026 so far

0

Through November 15, 2026

Human clinical research

0.0%

0 of 1 classified

Registered clinical trials

0

ClinicalTrials.gov

Randomized controlled trials

0

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

100.0%

1 animal · 0 in vitro · 0 computational

Records that only mention it

0

Not counted above

Status in the library: Research only. Groups: Cognitive and neurological peptides.

What to keep in mind

  • No human clinical publication is indexed: everything published so far is preclinical, a review or commentary.
  • Fewer than three randomized controlled trials are indexed.
  • More than 70% of the indexed publications are animal, cell or computational studies.
  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.

Publications by year

PE-22-28 publications by year and evidence

2017: 1012017
Counted PubMed publications by year of first publication. A larger bar is more publications, not stronger evidence.
Show the data
YearPreclinical (animal, in vitro, computational)
20171

Study types

Animal study1

Research areas

From MeSH major topics. A paper can be in several areas.

Neurological and mental health1

Registered clinical trials

A registration is not a result.

No registered trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

No human trial, systematic review or meta-analysis of PE-22-28 is indexed.

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.

    Frontiers in pharmacology · September 12, 2017 · Animal study · cited 36 times · open access

    PMID 28955242 · DOI 10.3389/fphar.2017.00643 · Animal studies

Latest publications

  1. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.

    Frontiers in pharmacology · September 12, 2017 · Animal study · cited 36 times · open access

    PMID 28955242 · DOI 10.3389/fphar.2017.00643 · Animal studies

Browse all 1 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: GVSWGLR; PE-22-28

((TITLE_ABS:"GVSWGLR" OR CHEM:"GVSWGLR") OR (TITLE_ABS:"PE-22-28" OR CHEM:"PE-22-28" OR TITLE_ABS:"PE22-28" OR CHEM:"PE22-28")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). PE-22-28 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/pe-22-28